

An Antimicrobial And Antifungal Activity Of Terbiunrare Metal Complex With Quinoline Derivative

Dr. H. R. Patel¹, Dr. H.D. Chaudhari²

^{1,2}Dept of Chemistry

¹Navjivan School of Science(P.G.), Deesa, India

²Hemchandracharya North Gujarat University, Patan, India

Abstract- The interaction of selected rare-earth metal ions with a biologically significant quinoline-based ligand has emerged as an important focus in current coordination chemistry research. In this investigation, a scarcely studied quinoline derivative was utilized to form coordination complexes by reacting it with various rare metal perchlorate solutions. The resulting solid complexes were thoroughly analyzed using a range of instrumental techniques. Additionally, their catalytic behavior was explored under both homogeneous and heterogeneous conditions. The synthesized complexes were also assessed for antimicrobial activity following standardized protocols. An attempt was made to establish correlations between the molecular structure and the observed chemical, physical, and biological characteristics.

Keywords- Quinoline-based ligand, Bioactive compound, Structural analysis, Microbial inhibition, Lanthanide (Tb³⁺) coordination complex

I. ANTIBACTERIAL ACTIVITY

The antibacterial potential of the synthesized compounds was assessed through in vitro bioassays. Four clinically significant bacterial strains — *Staphylococcus aureus*, *Escherichia coli*, *Streptococcus pyogenes*, and *Pseudomonas aeruginosa* — were selected as test organisms. Antimicrobial screening was conducted using the agar well diffusion technique, allowing for evaluation of bacterial growth inhibition zones [1-6]. A detailed summary of the observed antibacterial effects is provided in Table 1.

Table :- 1 Minimum Inhibitory Concentration (MIC) of Standard Antibacterial Drugs Against Selected Bacterial Strains

Standard Drug	E. coli (MTCC 443)	P. aeruginosa (MTCC 1688)	S. aureus (MTCC 96)	S. pyogenes (MTCC 442)	E. coli (MTCC 443)

Gentamycin	0.05 µg/mL	1 µg/mL	0.25 µg/mL	0.5 µg/mL	0.05 µg/mL
Ampicillin	100 µg/mL	—	250 µg/mL	100 µg/mL	100 µg/mL
Chloramphenicol	50 µg/mL	50 µg/mL	50 µg/mL	50 µg/mL	50 µg/mL
Ciprofloxacin	25 µg/mL	25 µg/mL	50 µg/mL	50 µg/mL	25 µg/mL
Norfloxacillin	10 µg/mL	10 µg/mL	10 µg/mL	10 µg/mL	10 µg/mL

Note: (—) indicates no detectable inhibition at tested concentration.

Table:- 2 Antibacterial activity of Quinoline derivative and its complex

Sr. No.	Compound Code	E. coli (MTC 443)	P. aeruginosa (MTCC 1688)	S. aureus (MTC C 96)	S. pyogenes (MTCC 442)
1	KYNA ligand	100 µg/mL	250 µg/mL	250 µg/mL	200 µg/mL
2	Tb-KYNA	95 µg/mL	228 µg/mL	252 µg/mL	206 µg/mL

The synthesized quinoline derivative (KYNA ligand) and its terbium complex (Tb-KYNA) exhibited moderate antibacterial activity against all tested bacterial strains. The osmium complex (Tb-KYNA) demonstrated slightly better activity than the free ligand, suggesting a possible enhancement of biological activity upon complexation. However, both compounds showed higher MIC values (lower potency) compared to the standard antibiotics.

A comparative assessment of the synthesized complexes with standard antibacterial agents revealed that, although the complexes demonstrated moderate to good inhibitory activity against all four tested bacterial strains, their effectiveness remained consistently lower than that of the reference antibiotics [7-14].

II. ANTIFUNGAL ACTIVITY

To explore the antifungal potential of the synthesized metal complexes, an agar well diffusion assay was employed against selected fungal pathogens: *Candida albicans*, *Aspergillus niger*, and *Aspergillus clavatus* [15-23]. The assessment was based on the ability of each compound to inhibit fungal growth, quantified by the diameter of the clear zones formed around the wells after incubation. Table 3 presents a comparative overview of the inhibitory performance of the tested complexes under controlled laboratory conditions.

Table:-3 Minimum Inhibitory Concentration (MIC) of Standard Antifungal Drugs Against Selected Fungal Strains

Standard Drug	C. albicans(MTC C 227)	A. niger(MTC C 282)	A. clavatus(MTC C 1323)
Nystatin	100 µg/mL	100 µg/mL	100 µg/mL
Griseofulvin	500 µg/mL	100 µg/mL	100 µg/mL

Table:- 4 Minimum Fungicidal Concentration (MFC) of Synthesized Compounds Against Selected Fungal Strains

Sr. No.	Compound Code	C. albicans(MT CC 227)	A. niger(MT CC 282)	A. clavatus(MT CC 1323)
1	KYNA ligand	1000 µg/mL	500 µg/mL	500 µg/mL
2	Tb-KYNA	577 µg/mL	1068 µg/mL	1104 µg/mL

A comparative analysis between the antifungal performance of the synthesized complexes and that of standard antimicrobial agents indicates that, while the complexes exhibit moderate to appreciable inhibitory activity against all three fungal strains tested, their effectiveness does not surpass that of the reference drugs.[24-29] The results suggest potential for biological application, though not as a replacement for established antifungal treatments.

CONCLUSION:

Kynurenic acid is a biologically significant molecule with notable physiological functions. To better understand its biological roles, complexation behavior, and potential biochemical applications, this study successfully synthesized and characterized three complexes of kynurenic acid with lanthanide ions. These complexes were thoroughly examined for their structural properties, as well as their catalytic and antimicrobial activities.

The results indicate that kynurenic acid readily forms stable complexes with lanthanide ions. These complexes exhibited outstanding catalytic abilities, particularly by significantly enhancing the rates of selected redox and carbon-carbon coupling reactions. Additionally, they displayed moderate antibacterial activity, suggesting potential for biomedical or pharmaceutical applications.

Overall, the findings suggest that complexes of kynurenic acid with lanthanides merge the biological relevance of the ligand with the functional versatility of the metal ions. This opens promising avenues for future research in catalysis and antimicrobial agent development.

III. ACKNOWLEDGEMENT

The authors sincerely acknowledge Hemchandracharya North Gujarat University, Patan, India for providing essential laboratory facilities, high-purity chemicals, and A-grade glassware necessary for the successful completion of this research work. We also extend our gratitude to the Central Instrumental Maintenance Facilities (CIMF), HNGU, Patan, for access to advanced analytical instruments and support in carrying out spectral analyses.

REFERENCES

- [1] Wimmerstedt, A., &Kahlmeter, G. (2008). Associated antimicrobial resistance in Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae and Streptococcus pyogenes. *Clinical Microbiology and Infection*, 14(4), 315-321.
- [2] Moussa, A., Nouredine, D., Mohamed, H. S., Abdelmelek, M., &Saad, A. (2012). Antibacterial activity of various honey types of Algeria against Staphylococcus aureus and Streptococcus pyogenes. *Asian Pacific journal of tropical medicine*, 5(10), 773-776.
- [3] Ann, L. C., Mahmud, S., Bakhori, S. K. M., Sirelkhatim, A., Mohamad, D., Hasan, H., ... & Rahman, R. A. (2014). Antibacterial responses of zinc oxide structures against

- Staphylococcus aureus, Pseudomonas aeruginosa and Streptococcus pyogenes. *Ceramics International*, 40(2), 2993-3001.
- [4] Knight, S. E. (1999). Goldenseal (*Hydrastis canadensis*) versus penicillin: a comparison of effects on *Staphylococcus aureus*, *Streptococcus pyogenes*, and *Pseudomonas aeruginosa*. *Bios*, 3-10.
- [5] Al-Kafaween, M. A., Al-Jamal, H. A. N., Hilmi, A. B. M., Elsahoryi, N. A., Jaffar, N., & Zahri, M. K. (2020). Antibacterial properties of selected Malaysian Tualang honey against *Pseudomonas aeruginosa* and *Streptococcus pyogenes*. *Iranian Journal of Microbiology*, 12(6), 565.
- [6] Wilkinson, J. M., & Cavanagh, H. M. (2005). Antibacterial activity of 13 honeys against *Escherichia coli* and *Pseudomonas aeruginosa*. *Journal of medicinal food*, 8(1), 100-103.
- [7] Dafale, N. A., Semwal, U. P., Rajput, R. K., & Singh, G. N. (2016). Selection of appropriate analytical tools to determine the potency and bioactivity of antibiotics and antibiotic resistance. *Journal of pharmaceutical analysis*, 6(4), 207-213.
- [8] Noumedem, J. A., Mihasan, M., Kuate, J. R., Stefan, M., Cojocar, D., Dzoyem, J. P., & Kuete, V. (2013). In vitro antibacterial and antibiotic-potential activities of four edible plants against multidrug-resistant gram-negative species. *BMC Complementary and Alternative Medicine*, 13(1), 190.
- [9] Chung, P. Y., Navaratnam, P., & Chung, L. Y. (2011). Synergistic antimicrobial activity between pentacyclic triterpenoids and antibiotics against *Staphylococcus aureus* strains. *Annals of clinical microbiology and antimicrobials*, 10(1), 25.
- [10] Blaser, J. U. R. G., Stone, B. B., Groner, M. C., & Zinner, S. H. (1987). Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. *Antimicrobial agents and chemotherapy*, 31(7), 1054-1060.
- [11] Stokes, N. R., Baker, N., Bennett, J. M., Berry, J., Collins, I., Czaplewski, L. G., ... & Haydon, D. J. (2013). An improved small-molecule inhibitor of FtsZ with superior in vitro potency, drug-like properties, and in vivo efficacy. *Antimicrobial agents and chemotherapy*, 57(1), 317-325.
- [12] Corbett, D., Wise, A., Langley, T., Skinner, K., Trimby, E., Birchall, S., ... & Lister, T. (2017). Potentiation of antibiotic activity by a novel cationic peptide: potency and spectrum of activity of SPR741. *Antimicrobial agents and chemotherapy*, 61(8), 10-1128.
- [13] Rodríguez-Melcón, C., Alonso-Calleja, C., García-Fernández, C., Carballo, J., & Capita, R. (2021). Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) for twelve antimicrobials (biocides and antibiotics) in eight strains of *Listeria monocytogenes*. *Biology*, 11(1), 46.
- [14] Aumeeruddy-Elalfi, Z., Gurib-Fakim, A., & Mahomoodally, M. F. (2016). Chemical composition, antimicrobial and antibiotic potentiating activity of essential oils from 10 tropical medicinal plants from Mauritius. *Journal of Herbal Medicine*, 6(2), 88-95.
- [15] Chauhan, N., Latge, J. P., & Calderone, R. (2006). Signalling and oxidant adaptation in *Candida albicans* and *Aspergillus fumigatus*. *Nature Reviews Microbiology*, 4(6), 435-444.
- [16] Pfaller, M. A., & Diekema, D. J. (2004). Rare and emerging opportunistic fungal pathogens: concern for resistance beyond *Candida albicans* and *Aspergillus fumigatus*. *Journal of clinical microbiology*, 42(10), 4419-4431.
- [17] Karkowska-Kuleta, J., Rapala-Kozik, M., & Kozik, A. (2009). Fungi pathogenic to humans: molecular bases of virulence of *Candida albicans*, *Cryptococcus neoformans* and *Aspergillus fumigatus*. *Acta Biochimica Polonica*, 56(2).
- [18] Stuehler, C., Khanna, N., Bozza, S., Zelante, T., Moretti, S., Kruhm, M., ... & Topp, M. S. (2011). Cross-protective TH1 immunity against *Aspergillus fumigatus* and *Candida albicans*. *Blood, The Journal of the American Society of Hematology*, 117(22), 5881-5891.
- [19] Waksman, S. A., Horning, E. S., & Spencer, E. L. (1943). Two antagonistic fungi, *Aspergillus fumigatus* and *Aspergillus clavatus*, and their antibiotic substances. *Journal of Bacteriology*, 45(3), 233-248.
- [20] Singh, J., Rimek, D., & Kappe, R. (2006). Intrinsic in vitro susceptibility of primary clinical isolates of *Aspergillus fumigatus*, *Aspergillus terreus*, *Aspergillus nidulans*, *Candida albicans* and *Candida lusitanae* against amphotericin B. *Mycoses*, 49(2), 96-103.
- [21] Macreadie, I. G., Johnson, G., Schlosser, T., & Macreadie, P. I. (2006). Growth inhibition of *Candida* species and *Aspergillus fumigatus* by statins. *FEMS microbiology letters*, 262(1), 9-13.
- [22] Hatano, K., Morishita, Y., Nakai, T., & Ikeda, F. (2002). Antifungal mechanism of FK463 against *Candida albicans* and *Aspergillus fumigatus*. *The Journal of Antibiotics*, 55(2), 219-222.
- [23] Steinbach, W. J., Schell, W. A., Blankenship, J. R., Onyewu, C., Heitman, J., & Perfect, J. R. (2004). In vitro interactions between antifungals and immunosuppressants against *Aspergillus fumigatus*. *Antimicrobial Agents and Chemotherapy*, 48(5), 1664-1669.

- [24] Lin, Y., Betts, H., Keller, S., Cariou, K., & Gasser, G. (2021). Recent developments of metal-based compounds against fungal pathogens. *Chemical Society Reviews*, 50(18), 10346-10402.
- [25] Rehman, S. U., Chohan, Z. H., Gulnaz, F., & Supuran, C. T. (2005). In-vitro antibacterial, antifungal and cytotoxic activities of some coumarins and their metal complexes. *Journal of Enzyme Inhibition and Medicinal Chemistry*, 20(4), 333-340.
- [26] Stevanović, N. L., Aleksic, I., Kljun, J., SkaroBogojevic, S., Veselinovic, A., Nikodinovic-Runic, J., ... & Glišić, B. Đ. (2020). Copper (II) and zinc (II) complexes with the clinically used fluconazole: comparison of antifungal activity and therapeutic potential. *Pharmaceuticals*, 14(1), 24.
- [27] Mimouni, M. F. Z. K., Khardli, F. Z., Warad, I., Ahmad, M., Mubarak, M. S., Sultana, S., & Hadda, T. B. (2014). Antimicrobial activity of naturally occurring antibiotics monensin, lasalocid and their metal complexes. *J. Mater. Environ. Sci*, 5(1), 207-214.
- [28] Opletalová, V., Kalinowski, D. S., Vejsova, M., Kunes, J., Pour, M., Jampilek, J., ... & Richardson, D. R. (2008). Identification and characterization of thiosemicarbazones with antifungal and antitumor effects: cellular iron chelation mediating cytotoxic activity. *Chemical Research in Toxicology*, 21(9), 1878-1889.
- [29] Ahmed, G. E., Elshahid, Z. A., El-Sawy, E. R., Abdel-Aziz, M. S., & Abdel-Aziem, A. (2024). Synthesis, biofilm formation inhibitory, and inflammation inhibitory activities of new coumarin derivatives. *Scientific Reports*, 14(1), 9106.
- [30] cup method. *Industrial crops and products*, 32(3), (2010) p-375-380.
- [5] FREDELL, W.. ANTISEPTIC POWDERS. *Antiseptics, Disinfectants, Fungicides, and Chemical and Physical Sterilization*, (1954)p-349.
- [6] Hiemstra, P. S., Maassen, R. J., Stolk, J., Heinzel-Wieland, R., Steffens, G. J., & Dijkman, J. H. Antibacterial activity of antileukoprotease. *Infection and immunity*, 64(11), (1996).p-4520-4524.
- [7] Powers, J. P. S., & Hancock, R. E. The relationship between peptide structure and antibacterial activity. *Peptides*, 24(11), (2003).p-1681-1691.
- [8] Slavin, Y. N., Asnis, J., Hírfeli, U. O., & Bach, H. Metal nanoparticles: understanding the mechanisms behind antibacterial activity. *Journal of nanobiotechnology*, 15, (2017).p-1-20.
- [9] Farhadi, F., Khameneh, B., Iranshahi, M., & Iranshahi, M.. Antibacterial activity of flavonoids and their structure–activity relationship: An update review. *Phytotherapy Research*, 33(1), (2019)p-13-40.
- [10] Prabuseenivasan, S., Jayakumar, M., & Ignacimuthu, S. In vitro antibacterial activity of some plant essential oils. *BMC complementary and alternative medicine*, 6(1), (2006). P-1-8.
- [11] Prashanth, D., Asha, M. K., & Amit, A. (2001). Antibacterial activity of Punicagranatum. *Fitoterapia*, 72(2), (2001). P-171-173.
- [12] Verma, V. C., Kharwar, R. N., & Gange, A. C. Biosynthesis of antimicrobial silver nanoparticles by the endophytic fungus *Aspergillus clavatus*. *Nanomedicine*, 5(1), (2010). P-33-40.
- [13] Jeyaraj Pandian, C., Palanivel, R., & Dhanasekaran, S. Screening antimicrobial activity of nickel nanoparticles synthesized using *Ocimum sanctum* leaf extract. *Journal of Nanoparticles*, 2016, (2016). P-1-13.
- [14] Bhalodia, N. R., & Shukla, V. J. Antibacterial and antifungal activities from leaf extracts of *Cassia fistula* L.: An ethnomedicinal plant. *Journal of advanced pharmaceutical technology & research*, 2(2), (2011). p-104.
- [15] Patel, N. B., & Shaikh, F. M. New 4-thiazolidinones of nicotinic acid with 2-amino-6-methylbenzothiazole and their biological activity. *Scientiapharmaceutica*, 78(4), (2010). P-753-766.
- [16] Nazmul, M. H. M., Salmah, I., Syahid, A., & Mahmood, A. A. In-vitro screening of antifungal activity of plants in Malaysia. *Biomed Res*, 22(1), (2011). p-28-30.
- [17] Zhao, Z., Wang, Q., Wang, K., Brian, K., Liu, C., & Gu, Y. Study of the antifungal activity of *Bacillus vallismortis* ZZ185 in vitro and identification of its antifungal components. *Bioresource technology*, 101(1), (2010). P-292-297.

REFERENCES

- [1] Manawar, R. B., Gondaliya, M. B., Mamtora, M. J., & Shah, M.. Synthesis and bioactivity study of 2-((E)-((E)-2, 6-dichlorobenzylidene) hydrazono) methyl phenol have N, O-Bidentate ligand site and it's metal complex. *World Scientific News*, (126), (2019) p-222-247.
- [2] Rose, S. B., & Miller, R. E. Studies with the agar cup-plate method: I. A standardized agar cup-plate technique. *Journal of bacteriology*, 38(5), (1939)p-525-537.
- [3] Miller, R. E., & Rose, S. B. Studies with the Agar Cup-Plate Method: III. The Influence of Agar on Mercury Antiseptics. *Journal of Bacteriology*, 38(5), (1939)p-539-547.
- [4] Roy, S., & Chatterjee, P. A non-toxic antifungal compound from the leaves of *Catharanthus roseus* characterized as 5-hydroxy flavone by UV spectroscopic analysis and evaluation of its antifungal property by agar-

- [18] Balouiri, M., Sadiki, M., & Ibnsouda, S. K. Methods for in vitro evaluating antimicrobial activity: A review. *Journal of pharmaceutical analysis*, 6(2), (2016). P-71-79.
- [19] Liu, C. H., Chen, X., Liu, T. T., Lian, B., Gu, Y., Caer, V., ... & Wang, B. T. Study of the antifungal activity of *Acinetobacterbaumannii* LCH001 in vitro and identification of its antifungal components. *Applied microbiology and biotechnology*, 76, (2007). P-459-466.
- [20] Bagiu, R. V., Vlaicu, B., & Butnariu, M. Chemical composition and in vitro antifungal activity screening of the *Allium ursinum* L.(Liliaceae). *International journal of molecular sciences*, 13(2), (2012). P-1426-1436.
- [21] Pinzari, F., Cuadros, J., Napoli, R., Canfora, L., & Bardají, D. B. Routes of phlogopite weathering by three fungal strains. *Fungal biology*, 120(12), (2016). P-1582-1599.
- [22] Zeng, X., Su, S., Jiang, X., Li, L., Bai, L., & Zhang, Y. Capability of pentavalent arsenic bioaccumulation and biovolatilization of three fungal strains under laboratory conditions. *Clean–Soil, Air, Water*, 38(3), (2010). P-238-241.
- [23] Turaeva, B., Soliev, A., Eshboev, F., Kamolov, L., Azimova, N., Karimov, H., ... & Khamidova, K. The use of three fungal strains in producing of indole-3-acetic acid and gibberellic acid. *Plant Cell Biotechnology and Molecular Biology*, 21(35-36), (2020). P-32-43.
- [24] Fenice, M., Selbmann, L., Zucconi, L., & Onofri, S. Production of extracellular enzymes by Antarctic fungal strains. *Polar Biology*, 17, (1997). P-275-280.